These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27226584)

  • 1. Tranilast Blocks the Interaction between the Protein S100A11 and Receptor for Advanced Glycation End Products (RAGE) V Domain and Inhibits Cell Proliferation.
    Huang YK; Chou RH; Yu C
    J Biol Chem; 2016 Jul; 291(27):14300-14310. PubMed ID: 27226584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking the Interactions between Calcium-Bound S100A12 Protein and the V Domain of RAGE Using Tranilast.
    Chiou JW; Fu B; Chou RH; Yu C
    PLoS One; 2016; 11(9):e0162000. PubMed ID: 27598566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentamidine blocks the interaction between mutant S100A5 and RAGE V domain and inhibits the RAGE signaling pathway.
    Cho CC; Chou RH; Yu C
    Biochem Biophys Res Commun; 2016 Aug; 477(2):188-94. PubMed ID: 27297108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking the interaction between S100A9 protein and RAGE V domain using S100A12 protein.
    Katte R; Yu C
    PLoS One; 2018; 13(6):e0198767. PubMed ID: 29902210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking the interface region amongst S100A6 and RAGE V domain via S100B protein.
    Sung HY; Dowarha D; Chou RH; Yu C
    Biochem Biophys Res Commun; 2020 Dec; 533(3):332-337. PubMed ID: 32958253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking the interaction between S100A9 and RAGE V domain using CHAPS molecule: A novel route to drug development against cell proliferation.
    Chang CC; Khan I; Tsai KL; Li H; Yang LW; Chou RH; Yu C
    Biochim Biophys Acta; 2016 Nov; 1864(11):1558-69. PubMed ID: 27524699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100B as an antagonist to block the interaction between S100A1 and the RAGE V domain.
    Khan MI; Su YK; Zou J; Yang LW; Chou RH; Yu C
    PLoS One; 2018; 13(2):e0190545. PubMed ID: 29444082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain.
    Dowarha D; Chou RH; Yu C
    ACS Omega; 2018 Aug; 3(8):9689-9698. PubMed ID: 31459098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insights into calcium-bound S100P and the V domain of the RAGE complex.
    Penumutchu SR; Chou RH; Yu C
    PLoS One; 2014; 9(8):e103947. PubMed ID: 25084534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysozyme as the anti-proliferative agent to block the interaction between S100A6 and the RAGE V domain.
    Khan MI; Dowarha D; Katte R; Chou RH; Filipek A; Yu C
    PLoS One; 2019; 14(5):e0216427. PubMed ID: 31071146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches.
    Xie J; Burz DS; He W; Bronstein IB; Lednev I; Shekhtman A
    J Biol Chem; 2007 Feb; 282(6):4218-31. PubMed ID: 17158877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of the S100A6 mutant (C3S) with the V domain of the receptor for advanced glycation end products (RAGE).
    Mohan SK; Gupta AA; Yu C
    Biochem Biophys Res Commun; 2013 May; 434(2):328-33. PubMed ID: 23537648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Anti-Cancer Activity of Pentamidine and Its Derivatives (WLC-4059) Is through Blocking the Interaction between S100A1 and RAGE V Domain.
    Parveen N; Chiu WJ; Shen LC; Chou RH; Sun CM; Yu C
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tranilast inhibits angiotensin II-induced myocardial fibrosis through S100A11/ transforming growth factor-β (TGF-β1)/Smad axis.
    Chen Y; Huang M; Yan Y; He D
    Bioengineered; 2021 Dec; 12(1):8447-8456. PubMed ID: 34663163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Trp triad within the V-domain of the receptor for advanced glycation end products modulates folding, stability and ligand binding.
    Indurthi VSK; Jensen JL; Leclerc E; Sinha S; Colbert CL; Vetter SW
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31912881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resonance assignments of Ca²⁺-bound human S100A11.
    Hung KW; Chang YM; Yu C
    Biomol NMR Assign; 2013 Oct; 7(2):211-4. PubMed ID: 22825890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of S100A13 with C2 domain of receptor for advanced glycation end products (RAGE).
    Rani SG; Sepuru KM; Yu C
    Biochim Biophys Acta; 2014 Sep; 1844(9):1718-28. PubMed ID: 24982031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Structure of the RAGE:S100A6 Complex Reveals a Unique Mode of Homodimerization for S100 Proteins.
    Yatime L; Betzer C; Jensen RK; Mortensen S; Jensen PH; Andersen GR
    Structure; 2016 Dec; 24(12):2043-2052. PubMed ID: 27818100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products.
    Cecil DL; Johnson K; Rediske J; Lotz M; Schmidt AM; Terkeltaub R
    J Immunol; 2005 Dec; 175(12):8296-302. PubMed ID: 16339570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling.
    Teng F; Jiang J; Zhang J; Yuan Y; Li K; Zhou B; Zhou X; Liu W; Zhang P; Liu D; Zheng M; Lu Y; Zhang H
    Metabolism; 2021 Apr; 117():154725. PubMed ID: 33571540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.